Partner Content
This research was conducted by Longitude, a Financial Times group company and part of FT Marketing Services; the FT’s commercial thought leadership offering.

The Global Biopharma
Resilience Index

In the wake of the greatest public health crisis in recent memory, the role of the pharma and biopharma industry in the lives of populations globally has taken on a growing importance as it fights to take on the Covid-19 pandemic.

Cytiva’s Global Biopharma Resilience Index - based on a survey of more than 1,000 senior biopharma executives - takes a holistic look at the industry across five key pillars at a time when its health is vital. Fresh data shows there is work to be done to secure its future.

To dive into the highlights and key findings of the index, see the pillars headlining each article, and take a closer look at the interactive data visualisation below.

A gap between high income and lower income countries needs to be bridged to avert shortages of critical drug supplies, and disruptions to global supply chains expose lacking support for talent and manufacturing in domestic markets.

But through insights from leading experts, the industry can blaze a trail forward to a more resilient future. Here’s the state of pharma and biopharma in the midst of its biggest challenge yet.

Explore our content

Biopharma 2021: The resilience rethink Read more
Global or local? Biopharma's supply chain challenge Read more
Biopharma reaches for homegrown talent Read more
Biopharma R&D needs more collaboration Read more
Shifting biopharma's manufacturing into the fast lane Read more
Making policy work for the biopharma industry Read more